Amneal Pharmaceuticals (AMRX) Current Leases (2017 - 2026)

Amneal Pharmaceuticals' Current Leases history runs 10 years deep, the most recent figure standing at $8.9 million for Q1 2026.

• On a quarterly basis, Current Leases rose 158.68% year-over-year to $8.9 million in Q1 2026; TTM through Mar 2026 was $8.9 million, a 158.68% increase from a year earlier, with the FY2025 full-year figure at $2.7 million, down 20.35% from the prior year.
• Current Leases rose to $8.9 million in Q1 2026 per AMRX's latest filing, from $2.7 million in the prior quarter.
• Across five years, Current Leases topped out at $9.8 million in Q3 2023 and bottomed at $2.7 million in Q4 2025.
• The 5-year median for Current Leases is $3.3 million (2024), against an average of $4.9 million.
• Across the five-year window, Current Leases jumped 215.67% in 2022 and slumped 66.14% in 2024, its largest moves.
• Year by year, Current Leases stood at $8.3 million in 2022, then tumbled by 66.05% to $2.8 million in 2023, then grew by 20.21% to $3.4 million in 2024, then retreated by 20.35% to $2.7 million in 2025, then jumped by 229.83% to $8.9 million in 2026.
• Per Business Quant, the three latest AMRX Current Leases figures stand at $8.9 million (Q1 2026), $2.7 million (Q4 2025), and $8.0 million (Q3 2025).